Monday, January 6, 2013
DARPA-BAA-14-09 Systems-Based Neurotechnology for Emerging Therapies (SUBNETS) DARPA - Defense Sciences Office — Department of Defense
Although being touted as a means by which to "HELP" - the DoD NEVER does anything for just ONE PURPOSE. They look at the Advances in Controlling OTHER PEOPLES BRAIN FUNCTIONS as a MEANS OF CONTROL -
In the case of the Solicitation for Funding by DARPA to place brain implants into "subjects", the Technical Areas have to do with Monitoring Neural Output, and then using existing or new BIO-technological means by which to "stimulate aka ZAP neurons" or a series of neurons in order to '"elevate symptoms." aka control behavioral functions....
| DARPA seeks to develop a new understanding of complex, systems-based disorders of the brain. A major goal of this effort is to deliver a platform technology for precise therapy in humans living with neuropsychiatric and neurologic disease, including veterans and active duty soldiers suffering from mental health issues. Methods developed through this program will use neural recording and stimulation to close the loop on therapeutic treatment in individuals who receive minimal benefits from currently available treatments. This program could lead to improved knowledge of multiple neural subnetworks of the brain that are involved in disease and illness. This program combines novel device development, complex modeling of behaving human neural systems, clinical neurology, and animal research in order to advance the understanding and translation of safe, effective neurotechnological therapies. |
This is nothing more than Coercive Mechanical manipulation of Cognitive, Motor, Central Nervous System, and/or Behavioral Functions. aka MIND CONTROL
Thus, this is a means by which to come out of the black ops closet, and claim this is for the purpose of "ideas" or "proof of principle" but in reality they have long since and criminally been experimenting on Human Subject in the form of Targeted Individual's for YEARS.
This approach should advance neuropsychiatry beyond the realm of dialogue-driven observations and
resultant trial and error and into the realm of therapy driven by quantifiable characteristics of neural
state. In doing so, SUBNETS will create one of the most comprehensive datasets of systems-based brain
activity ever recorded.
resultant trial and error and into the realm of therapy driven by quantifiable characteristics of neural
state. In doing so, SUBNETS will create one of the most comprehensive datasets of systems-based brain
activity ever recorded.
For purposes of this program, DARPA is specifically interested in evaluating the underlying systems,
which contribute to the following conditions as described by the Diagnostic and Statistical Manual of
Mental Disorders (DSM-V):
• • • •
Post-Traumatic Stress Disorder (PTSD) Major Depression Borderline Personality Disorder General
Anxiety Disorder
Anxiety Disorder
Additionally, DARPA is interested in evaluating the representation in the central nervous system of the
following three conditions:
........
following three conditions:
........
• TBI • Substance Abuse/Addiction • Fibromyalgia/Chronic Pain
HOW MANY FIELDS ARE INVOLVED
DARPA expects that successful teams will span across disciplines including psychiatry, neurosurgery,
microelectronics, neuroscience, statistics, and computational modeling. All teams should have access to
sufficient clinical populations to allow the recruitment of volunteer research participants from each of
the diseases and disorders of interest. Teams that propose to Technical Area Two should have familiarity
with the Food and Drug Administration (FDA) regulations regarding implanted devices. Teams that
propose to Technical Area Three should have currently operating facilities for advanced animal
modeling, such as non-human primate research.
microelectronics, neuroscience, statistics, and computational modeling. All teams should have access to
sufficient clinical populations to allow the recruitment of volunteer research participants from each of
the diseases and disorders of interest. Teams that propose to Technical Area Two should have familiarity
with the Food and Drug Administration (FDA) regulations regarding implanted devices. Teams that
propose to Technical Area Three should have currently operating facilities for advanced animal
modeling, such as non-human primate research.
Technical Area One (TA One): aka (MAPPING THE BRAIN VIA NEURAL OUTPUT)
TA One is comprised of clinical trials in order to establish mechanistic models of awake, behaving
human brain activity. In Phase One, investigators should propose a method to establish models for
two neuropsychiatric systems and one neurological system. These methods should demonstrate the
capacity to record neural signals from participants and associate these signals with behavior.
Additionally, models should describe how stimulation could, without impacting behavior or symptoms
not related to their primary disease outcomes, effect research participants and provide alleviation from
their disease- related symptoms. In Phase Two, investigators will be responsible for modeling the
additional two neuropsychiatric systems and the final two neurological systems. DARPA is particularly
interested in proposals that advance understanding of mechanisms of change, plasticity, or adaptation
in neural systems over time in response to stimulation.
human brain activity. In Phase One, investigators should propose a method to establish models for
two neuropsychiatric systems and one neurological system. These methods should demonstrate the
capacity to record neural signals from participants and associate these signals with behavior.
Additionally, models should describe how stimulation could, without impacting behavior or symptoms
not related to their primary disease outcomes, effect research participants and provide alleviation from
their disease- related symptoms. In Phase Two, investigators will be responsible for modeling the
additional two neuropsychiatric systems and the final two neurological systems. DARPA is particularly
interested in proposals that advance understanding of mechanisms of change, plasticity, or adaptation
in neural systems over time in response to stimulation.
Technical Area Two (TA Two): AKA ( ZAPPING the Brain to alter cognitive, motor, central
nervous system and/or behaivoral functions)
nervous system and/or behaivoral functions)
TA Two encompasses the hardware development component in order to create safe and effective sensing
and stimulation systems. These systems may be based on currently available commercial technology, or
take on a new form-factor. Goals and metrics in this TA include the fabrication and testing of novel
devices, ensuring that the devices are amenable to the functionalization of models built in TA One,
and advancing the state-of- the art for weight, power, and actuation. Additionally, TA Two will include
tasks related to device acceptance by both the FDA and consultation with potential end users from the
clinical and patient communities.
and stimulation systems. These systems may be based on currently available commercial technology, or
take on a new form-factor. Goals and metrics in this TA include the fabrication and testing of novel
devices, ensuring that the devices are amenable to the functionalization of models built in TA One,
and advancing the state-of- the art for weight, power, and actuation. Additionally, TA Two will include
tasks related to device acceptance by both the FDA and consultation with potential end users from the
clinical and patient communities.
DARPA is not interested in simple modifications to existing technologies, but rather seeks to significantly
advance the capabilities of neural recording beyond those offered from current commercial-off-the-shelf
devices. For purposes of this proposal, proposers should not limit their understanding of neural recording
to the ability to record electrical potentials generated through synaptic activity, but may also address other
methods of recording neural activity, such as methods for measuring neurotransmitters. Proposals which
outline methods for recording non-electrical activity of neurons must also outline an appropriate FDA
strategy, to include package submission and Investigational Device Exemption (IDE) approval in Phase
One and package modifications in Phase Two.
advance the capabilities of neural recording beyond those offered from current commercial-off-the-shelf
devices. For purposes of this proposal, proposers should not limit their understanding of neural recording
to the ability to record electrical potentials generated through synaptic activity, but may also address other
methods of recording neural activity, such as methods for measuring neurotransmitters. Proposals which
outline methods for recording non-electrical activity of neurons must also outline an appropriate FDA
strategy, to include package submission and Investigational Device Exemption (IDE) approval in Phase
One and package modifications in Phase Two.
WHAT THIS DARPA SOLICITATION DOES IS LEGALLY VALIDATE THE CRIMINAL
CLAIMS I MADE ABOUT WHAT HAS ALREADY BEEN GOING ON - VIA A SENT
EMAIL TO THE LAW AND NEUROSCIENCE PROJECT OUTLINING BASICALLY
EVERYTHING THAT IS FROM THIS DEFENSE ADVANCED RESEARCH PROJECT
AGENCY 2013/2014 FUNDING SOLICITATION
CLAIMS I MADE ABOUT WHAT HAS ALREADY BEEN GOING ON - VIA A SENT
EMAIL TO THE LAW AND NEUROSCIENCE PROJECT OUTLINING BASICALLY
EVERYTHING THAT IS FROM THIS DEFENSE ADVANCED RESEARCH PROJECT
AGENCY 2013/2014 FUNDING SOLICITATION
From the DARPA Funding Proposal of October 24, 2013 DARPA-BAA-14-09
Systems-Based Neurotechnology for Emerging Therapies (SUBNETS):
Ethical, Legal, and Societal Implications (ELSI) of Neurotechnology for Disease Alleviation:
DARPA maintains its commitment to ensuring that efforts funded under this BAA adhere to ethical
and legal regulations currently in place for federally and DoD-funded research involving human and
animal use. Program developments will be discussed with the Presidential Commission for the Study
of Bioethical Issues, which advises the President on bioethical issues that may emerge as a
consequence of advances in biomedical science and technology. Respondents to this BAA should
address potential ethical, legal, and societal implications of the proposed technology. Specifically,
proposers should address patient populations who may benefit from the use of a novel technology
to address symptom severity.
This is what I wrote to the Presidential Commission for the Study of Bioethical Issues,
and sent to them via email for my Public Comment at their February 2-3, 2012
Gathering.SHOWS - Before even this Defense Advanced Research Project Agency
(DARPA) funding solicitation, Target's such as myself, had LONG SINCE OUTLINED
what was being done to them ILLEGALLY, CRIMINALLY, as
NON CONSENSUAL HUMAN GUINEA PIGS.
No comments:
Post a Comment